厄洛替尼靶向治疗联合化疗对老年晚期非小细胞肺癌患者生存质量及脑转移的影响研究

Effect on quality of life and brain metastases of Erlotinib therapy combine with chemotherapy in the treatment of elderly advanced non-small cell lung cancer patients

目的探究厄洛替尼靶向治疗联合化疗对老年晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的生存质量及脑转移的影响。方法选取2014年8月至21015年8月本院接诊的90例老年晚期NSCLC患者为研究对象,所有患者均符合NSCLC诊断标准,且通过DNA等基因突变检测。按照随机数表法将入选患者分为试验组(厄洛替尼靶向治疗联合吉西他滨和顺铂化疗)和对照组(吉西他滨联合顺铂化疗)。比较两组患者生存质量、脑转移和不良反应发生情况及疗效。结果治疗后试验组患者生理状况、社会/家庭状况、情感状况、功能状况、肺癌相关症状及癌症治疗功能性量表(FACT-L)总评分均显著高于对照组(P<0.05)。两组患者各不良反应发生率和总不良反应发生率比较均无显著差异(P>0.05)。试验组患者治疗总有效率显著高于对照组[93.33%(42/45)︰75.55%(34/45)](P<0.05)。试验组患者发生脑转移7例(15.56%),显著少于对照组[16例(35.56%)](P<0.05)。结论厄洛替尼靶向治疗联合化疗能够有效提高老年晚期NSCLC患者的生存质量,控制脑转移,临床疗效满意。

Objective To study the effect on quality of life and brain metastases of Erlotinib therapy combine with chemotherapy in the treatment of elderly advanced non-small cell lung cancer （NSCLC）. Method 90 elderly patients with advanced NSCLC who received therapy from August 2014 to August 2015 in our hospital were selected as research objects. All accord with the diagnostic criteria of NSCLC, and through DNA mutation detection. According to the random number table method, they were divided into experimental group （Erlotinib combined with Gemcitabine and Cisplatin） and control group （Gemcitabine combined with Cisplatin）. The quality of life, brain metastases, incidence of adverse reactions and curative effects between the two groups were observed. Result The physiological status, social/family status, emotional status, functional status, lung cancer related symptoms and total score of experimental group were significantly better than those of control group （P 〈 0.05）. There were no significant differences in the incidence of adverse reactions and total adverse reactions between the two groups （P 〉 0.05）. The total remission rate of experimental group was significantly higher than control group [93.33% （42/45） ： 75.55%（34/45）] （P 〈 0.05）. Experimental group of patients with brain metastases were 7 cases （15.56%）, was significantly lower than control group [16 cases （35.56%）] （P 〈 0.05）. Conclusion Erlotinib combined with chemotherapy can effectively improve the elderly patients with advanced NSCLC survival quality, control brain metastasis, can achieve satisfactory curative effect in clinical treatment.